MediciNova gets bounce after revealing clinical plan for MS therapy

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a

Read the full 278 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE